Huakang Biomedical Holdings Co Ltd
08622
Company Profile
Business description
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.
Contact
No.16 Yinkui Road
1-3 floor, Building D, Shenzhen Junxuan
Kui Xin Community, Kui Chong Office
Dapeng New District
Shenzhen
CHNT: +86 75533853878
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
90
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,569.10 | 112.30 | 1.33% |
| CAC 40 | 7,578.65 | 104.06 | 1.39% |
| DAX 40 | 20,609.79 | 35.11 | 0.17% |
| Dow JONES (US) | 43,221.55 | 703.27 | 1.65% |
| FTSE 100 | 8,353.02 | 51.89 | 0.63% |
| HKSE | 19,522.89 | 236.82 | 1.23% |
| NASDAQ | 19,511.23 | 466.84 | 2.45% |
| Nikkei 225 | 38,572.60 | 128.02 | 0.33% |
| NZX 50 Index | 13,000.67 | 57.10 | 0.44% |
| S&P 500 | 5,949.91 | 107.00 | 1.83% |
| S&P/ASX 200 | 8,327.00 | 113.70 | 1.38% |
| SSE Composite Index | 3,236.03 | 8.92 | 0.28% |